READ-ONLY DIGITIZATION RESULT
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.
J Clin Oncol · 2026-Feb-10 · PMID 41505697
Panel B提取完成待 EXE 对齐验证
OS
FIG A2. Kaplan-Meier estimates of RFS (A) and postresection OS (B) in patients who underwent secondary R0 surgery, according to treatment groups. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. FOLFOX, fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; NE, not estimable; OS, overall survival; R0, no residual tumor; RFS, relapse-free survival.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T16:59:45+00:00 |